ArticleFrontiers in cellular and infection microbiology2025
Computational identification of natural inhibitors targeting GroEL in
Article in Frontiers in cellular and infection microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Leptospirosis is a zoonotic disease caused by Methods: A structure-based virtual screening approach was performed using a library of 543,503 natural compounds from the Life Chemicals database. Top-ranked ligands were evaluated using molecular docking and physicochemical and pharmacokinetic property analyses. Density functional theory calculations were performed to assess electronic stability, followed by molecular dynamics simulations to evaluate ligand-protein complex stability. Principal component analysis and MM-PBSA binding free energy calculations were subsequently applied to characterize conformational dynamics and binding affinity. Results: Five compounds (F3385-2019, F1243-0200, F3139-0927, F2801-0179, and F1864-0208) exhibited strong binding affinities toward GroEL, with docking energies ranging from -10.34 to -8.26 kcal/mol. All shortlisted compounds complied with Lipinski's Rule of Five and demonstrated favorable pharmacokinetic properties. Molecular dynamics simulations and MM-PBSA analyses indicated stable ligand-protein interactions. Among the candidates, F1864-0208 and F1243-0200 emerged as the most stable and promising leads, whereas the remaining compounds showed moderate inhibition. Discussion: This study provides computational evidence supporting GroEL as a viable drug target in
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.